Telix Pharmaceuticals Ltd has released a press release.
1st Patient Dosed ProstACT Prostate Cancer Therapy Program
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Appendix 4C and Activities Report for December 2021 Quarter
- Capital Raise Presentation
- Telix completes $175M placement and launches $25M SPP
- Targeted Alpha Therapy for Bladder Cancer 1st patient dosed
- FDA Approves Telix Prostate Cancer Imaging Product Illuccix
Later from Telix Pharmaceuticals
- Sydney Airport to be removed from the S&P/ASX 200 Index
- Telix Granted Illuccix EU Regulatory Review Extension
- Commercial Distribution Agreement for Illuccix for Australia
- 2021 Full Year Results Presentation
- Cancellation of Share Purchase Plan
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals